Effects of Molidustat in the Treatment of Anemia in CKD

BACKGROUND AND OBJECTIVES: The efficacy and safety of molidustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, have been evaluated in three 16-week, phase 2b studies in patients with CKD and anemia who are not on dialysis (DaIly orAL treatment increasing endOGenoUs Erythropoietin [DIALOG...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin J Am Soc Nephrol
Hlavní autoři: Macdougall, Iain C., Akizawa, Tadao, Berns, Jeffrey S., Bernhardt, Thomas, Krueger, Thilo
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Nephrology 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6364546/
https://ncbi.nlm.nih.gov/pubmed/30559105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.02510218
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky